These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 9492773)

  • 21. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Sancho J; Behm FG; Hancock ML; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Pui CH; Campana D
    Blood; 2002 Jul; 100(1):52-8. PubMed ID: 12070008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.
    Ciudad J; San Miguel JF; López-Berges MC; Vidriales B; Valverde B; Ocqueteau M; Mateos G; Caballero MD; Hernández J; Moro MJ; Mateos MV; Orfao A
    J Clin Oncol; 1998 Dec; 16(12):3774-81. PubMed ID: 9850021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of minimal residual disease in peripheral blood prior to clinical relapse of childhood acute lymphoblastic leukaemia using PCR.
    Lal A; Kwan E; Haber M; Norris MD; Marshall GM
    Mol Cell Probes; 2001 Apr; 15(2):99-103. PubMed ID: 11292328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
    Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
    Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group.
    Brisco MJ; Condon J; Hughes E; Neoh SH; Nicholson I; Sykes PJ; Tauro G; Ekert H; Waters K; Toogood I
    Leukemia; 1993 Oct; 7(10):1514-20. PubMed ID: 8412313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin gene rearrangement in detection of minimal residual disease in acute lymphoblastic leukaemia.
    Nayyar A; Ahmed S
    J Ayub Med Coll Abbottabad; 2013; 25(1-2):159-61. PubMed ID: 25098084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphoblastic lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry.
    Jaworska-Posadzy A; Styczynski J; Kubicka M; Debski R; Rafinska-Kurylo B; Kolodziej B; Pogorzala M; Wysocki M
    Anticancer Res; 2011 Apr; 31(4):1453-7. PubMed ID: 21508402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Children with acute lymphoblastic leukemia: prognostic significance of polymerase-chain-reaction analysis of minimal residual disease].
    Steenbergen EJ; Verhagen OJ; van den Berg H; van Leeuwen EF; von dem Borne AE; van der Schoot CE
    Ned Tijdschr Geneeskd; 1996 Jan; 140(1):22-8. PubMed ID: 8569906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia.
    Uckun FM; Kersey JH; Haake R; Weisdorf D; Nesbit ME; Ramsay NK
    N Engl J Med; 1993 Oct; 329(18):1296-301. PubMed ID: 8413410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
    Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
    Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
    Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
    Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
    Drach J; Drach D; Glassl H; Gattringer C; Huber H
    Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
    Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry.
    Farahat N; Morilla A; Owusu-Ankomah K; Morilla R; Pinkerton CR; Treleaven JG; Matutes E; Powles RL; Catovsky D
    Br J Haematol; 1998 Apr; 101(1):158-64. PubMed ID: 9576196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
    Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
    Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse.
    Biondi A; Yokota S; Hansen-Hagge TE; Rossi V; Giudici G; Maglia O; Basso G; Tell C; Masera G; Bartram CR
    Leukemia; 1992 Apr; 6(4):282-8. PubMed ID: 1316978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.